(Q38730064)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

title

Aspirin and colorectal cancer: the promise of precision chemoprevention (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference

1 reference

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

author name string

David A Drew

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

Andrew T Chan

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

language of work or name

English

0 references

publication date

12 February 2016

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

published in

Nature Reviews Cancer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

page(s)

173-186

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrc.2016.4

7 March 2020

exact match

0 references

cites work

Cancer statistics, 2015

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin in the Chemoprevention of Colorectal Neoplasia: An Overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Prophylactic use of aspirin: systematic review of harms and approaches to mitigation in the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Routine Aspirin or Nonsteroidal Anti-inflammatory Drugs for the Primary Prevention of Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The role of aspirin in cancer prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Association of aspirin and NSAID use with risk of colorectal cancer according to genetic variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drug Use and Colorectal Cancer Risk: A Population-Based, Case-Control Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Alternate-day, low-dose aspirin and cancer risk: long-term observational follow-up of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

A genetic model for colorectal tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Recurrence rates for colorectal polyps.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

A randomized trial of aspirin to prevent colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin and folic acid for the prevention of recurrent colorectal adenomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Colorectal polyp prevention by daily aspirin use is abrogated among active smokers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin, Calcitriol, and Calcium Do Not Prevent Adenoma Recurrence in a Randomized Controlled Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Analysis of risk of bleeding complications after different doses of aspirin in 192,036 patients enrolled in 31 randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Prophylactic aspirin and risk of peptic ulcer bleeding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

CYP2C9 variants increase risk of colorectal adenoma recurrence and modify associations with smoking but not aspirin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The influence of UGT1A6 variants and aspirin use in a randomized trial of celecoxib for prevention of colorectal adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Cytochrome P450 2C9 variants influence response to celecoxib for prevention of colorectal adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Tissue-specific patterns of gene expression in the epithelium and stroma of normal colon in healthy individuals in an aspirin intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

No association between cyclooxygenase-2 and uridine diphosphate glucuronosyltransferase 1A6 genetic polymorphisms and colon cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The effect of UGT1A and UGT2B polymorphisms on colorectal cancer risk: haplotype associations and gene–environment interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: colon cancer family registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin for the prevention of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Cyclooxygenase-2: how good is it as a target for cancer chemoprevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Cyclooxygenase inhibitors: From pharmacology to clinical read-outs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The role of COX-2 in intestinal inflammation and colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Mechanistic aspects of COX-2 expression in colorectal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin and the risk of colorectal cancer in relation to the expression of COX-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Acceleration of intestinal polyposis through prostaglandin receptor EP2 in Apc(Delta 716) knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin use and risk of colorectal cancer according to BRAF mutation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Serrated neoplasia-role in colorectal carcinogenesis and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Genetics of the serrated pathway to colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The serrated pathway to colorectal carcinoma: current concepts and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

15-Hydroxyprostaglandin dehydrogenase is an in vivo suppressor of colon tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

15-Hydroxyprostaglandin dehydrogenase inactivation as a mechanism of resistance to celecoxib chemoprevention of colon tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Inactivating mutation in the prostaglandin transporter gene, SLCO2A1, associated with familial digital clubbing, colon neoplasia, and NSAID resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Quantification of the major urinary metabolite of PGE2 by a liquid chromatographic/mass spectrometric assay: determination of cyclooxygenase-specific PGE2 synthesis in healthy humans and those with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Urinary PGE-M: a promising cancer biomarker

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Urinary prostaglandin E2 metabolite and risk for colorectal adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Urinary PGE-M levels are associated with risk of colorectal adenomas and chemopreventive response to anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Urinary metabolites of prostanoids and risk of recurrent colorectal adenomas in the Aspirin/Folate Polyp Prevention Study (AFPPS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

21 January 2018

Eicosanoids and cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Polymorphisms predicted to alter function in prostaglandin E2 synthase and prostaglandin E2 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Decreased cyclooxygenase inhibition by aspirin in polymorphic variants of human prostaglandin H synthase-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Polymorphisms in PTGS1, PTGS2 and IL-10 do not influence colorectal adenoma recurrence in the context of a randomized aspirin intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence--data from a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Genetic variation in prostaglandin E2 synthesis and signaling, prostaglandin dehydrogenase, and the risk of colorectal adenoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Genetic variation in prostaglandin synthesis and related pathways, NSAID use and colorectal cancer risk in the Colon Cancer Family Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

PI3K/Akt signalling pathway and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Location of inhibitor binding sites in the human inducible prostaglandin E synthase, MPGES1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Microsomal glutathione transferase 1: mechanism and functional roles.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

mPGES-1 as a target for cancer suppression: A comprehensive invited review "Phospholipase A2 and lipid mediators".

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Genome-wide analysis of DNA methylation and the gene expression change in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

LMO3 interacts with neuronal transcription factor, HEN2, and acts as an oncogene in neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Wnt/beta-catenin signaling: components, mechanisms, and diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Molecular pathways: aspirin and Wnt signaling-a molecularly targeted approach to cancer prevention and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Prostaglandin E2 promotes colon cancer cell growth through a Gs-axin-beta-catenin signaling axis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin use, 8q24 single nucleotide polymorphism rs6983267, and colorectal cancer according to CTNNB1 alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

A common genetic risk factor for colorectal and prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The role of PGE2 in intestinal inflammation and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Definition of Prostaglandin E2-EP2 Signals in the Colon Tumor Microenvironment That Amplify Inflammation and Tumor Growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Inflammatory markers are associated with risk of colorectal cancer and chemopreventive response to anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

A prospective study of plasma inflammatory markers and risk of colorectal cancer in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Interleukin-6 and risk of colorectal cancer: results from the CLUE II cohort and a meta-analysis of prospective studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The diverse roles of nonsteroidal anti-inflammatory drug activated gene (NAG-1/GDF15) in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The TGF-β superfamily cytokine, MIC-1/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

A prospective study of macrophage inhibitory cytokine-1 (MIC-1/GDF15) and risk of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin use and survival after diagnosis of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Effect of aspirin and NSAIDs on risk and survival from colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin and COX-2 inhibitor use in patients with stage III colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin use and reduced risk of fatal colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Effect of daily aspirin on risk of cancer metastasis: a study of incident cancers during randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin and colorectal cancer: back to the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Impact of regular aspirin use on overall and cancer-specific survival in patients with colorectal cancer harboring a PIK3CA mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Association between rectal optical signatures and colonic neoplasia: potential applications for screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Rectal Optical Markers for In Vivo Risk Stratification of Premalignant Colorectal Lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin Reduces Plasma Concentrations of the Oncometabolite 2-Hydroxyglutarate: Results of a Randomized, Double-Blind, Crossover Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Combination chemoprevention for colon cancer targeting polyamine synthesis and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Targeting polyamine metabolism and function in cancer and other hyperproliferative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Polyamines and cancer: old molecules, new understanding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomas: a randomized placebo-controlled, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Pronounced reduction in adenoma recurrence associated with aspirin use and a polymorphism in the ornithine decarboxylase gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Ornithine decarboxylase polymorphism modification of response to aspirin treatment for colorectal adenoma prevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Ornithine decarboxylase G316A genotype is prognostic for colorectal adenoma recurrence and predicts efficacy of aspirin chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Ornithine decarboxylase-1 polymorphism, chemoprevention with eflornithine and sulindac, and outcomes among colorectal adenoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Variants downstream of the ornithine decarboxylase gene influence risk of colorectal adenoma and aspirin chemoprevention

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomize

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Gastrointestinal adverse effects of short-term aspirin use: a meta-analysis of published randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin: a historical and contemporary therapeutic overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Genetic alterations during colorectal-tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin and the Risk of Colorectal Cancer in Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Molecular genetics of colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Natural history of adenomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

The evolution of colorectal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Spectral biomarkers for chemoprevention of colonic neoplasia: a placebo-controlled double-blinded trial with aspirin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Prospective study of urinary prostaglandin E2 metabolite and colorectal cancer risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Urine PGE-M: A Metabolite of Prostaglandin E2 as a Potential Biomarker of Advanced Colorectal Neoplasia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin and NSAID chemoprevention, gene-environment interactions, and risk of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Aspirin use and the risk for colorectal cancer and adenoma in male health professionals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2016.4

Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis

31 March 2020

1 reference

12 December 2020

Genetic disruption of Ptgs-1, as well as Ptgs-2, reduces intestinal tumorigenesis in Min mice

1 reference

12 December 2020

Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis.

1 reference

12 December 2020

Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial

1 reference

12 December 2020

Expression of COX-2 in platelet-monocyte interactions occurs via combinatorial regulation involving adhesion and cytokine signaling

1 reference

12 December 2020

High cyclooxygenase-2 expression is associated with advanced stages in colorectal cancer

1 reference

12 December 2020

Current concepts in colorectal cancer prevention with cyclooxygenase inhibitors.

1 reference

12 December 2020

Post-operative aspirin use and colorectal cancer-specific survival in patients with stage I-III colorectal cancer

1 reference

12 December 2020

ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours

1 reference

12 December 2020

Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRC.2016.4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

7 March 2020

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26868177%20AND%20SRC:MED&resulttype=core&format=json

7 March 2020

1 reference